Detalhe da pesquisa
1.
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results.
Oncologist
; 28(5): e309-e312, 2023 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36994854
2.
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med
; 381(4): 338-348, 2019 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31340094
3.
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Lancet Oncol
; 22(11): 1541-1559, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34600602
4.
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
N Engl J Med
; 377(4): 352-360, 2017 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28578607
5.
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Lancet Oncol
; 19(2): 194-206, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29326030
6.
Radiographic progression-free survival in the ACIS trial for prostate cancer - Authors' reply.
Lancet Oncol
; 23(1): e5-e6, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34973233
7.
Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
Int J Urol
; 23(5): 404-11, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26879374
8.
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
Lancet Oncol
; 16(2): 152-60, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25601341
9.
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Lancet Oncol
; 15(11): 1263-8, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25242048
10.
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
Prostate Cancer Prostatic Dis
; 26(1): 156-161, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36209239
11.
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.
Eur Urol Oncol
; 2023 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38072759
12.
Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
Cancer Chemother Pharmacol
; 89(2): 151-164, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34977972
13.
Erdafitinib's effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer.
CPT Pharmacometrics Syst Pharmacol
; 11(5): 569-580, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34755484
14.
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
Eur Urol Focus
; 8(4): 958-967, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34479838
15.
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302.
Eur J Cancer
; 170: 296-304, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35568679
16.
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Blood
; 114(6): 1166-73, 2009 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-19470696
17.
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group.
Clin Cancer Res
; 27(9): 2408-2415, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33563637
18.
Apalutamide and Overall Survival in Prostate Cancer.
Eur Urol
; 79(1): 150-158, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32907777
19.
Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer.
ESMO Open
; 5(6): e000943, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33184097
20.
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
Eur Urol
; 77(4): 494-500, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31843335